A randomized controlled trial to assess the efficacy and cost-effectiveness of urinary catheters with silver alloy coating in spinal cord injured patients: trial protocol

Bonfill, Xavier; Rigau, David; Jauregui-Abrisqueta, M.L.; Chacón, J.M. Barrera; Barrera, S. Salvador de la; Alemán-Sánchez, Carolina; Bea-Muñoz, Manuel; Pérez, Susana Moraleda; Durán, Albert Borau i; Quirós, Juan Ramón Espinosa; Romano, Luís Ledesma; Fuertes, M. Esteban; Araya, Ignacio; Martínez-Zapata, Ma José

doi:10.1186/1471-2490-13-38

Cited by 9 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, a multicenter randomized controlled trial involving participants requiring short-term (≤14 days) catheterization compared commercially available Ag alloy-coated latex catheters (>2000 patients) with standard PTFE-coated latex catheters (>2000 patients) and concluded that the Ag alloy-coated catheters were not effective in reducing the incidence of symptomatic CAUTIs . On the other hand, two smaller studies showed 35% and 47% reductions in the CAUTIs with Ag alloy and Ag-alloy hydrogel catheters, respectively, compared to the standard catheter. , The reasons for the differences in findings are likely to be multifactorial involving how the clinical trials were carried out and the nature of the Ag-coated catheters such as Ag release rate and surface properties.…”

Section: Dual-functional Coatings For Biomedical Applicationsmentioning

confidence: 99%

Polymer-Based Coatings with Integrated Antifouling and Bactericidal Properties for Targeted Biomedical Applications

Mitra

Kang

Neoh

2021

ACS Appl. Polym. Mater.

View full text Add to dashboard Cite

One of the most detrimental consequences of surface colonization by bacteria is healthcare-associated infections (HAIs), which contribute to increased patient mortality and morbidity. Medical devices inserted into the body provide a route for bacterial migration and conducive surfaces for their attachment and proliferation. Antibacterial coatings can potentially minimize bacterial colonization and consequently reduce the occurrence of HAIs. Antibacterial coatings function by either inhibiting the attachment of bacteria (antifouling coatings) or killing bacteria attached to the surface and/or in the vicinity (bactericidal coatings). On an antifouling coating, any bacterium that manages to attach will proliferate, while on bactericidal coatings, the accumulation of dead bacteria and debris provides opportunities for other bacteria to colonize the surface. As such, the integration of antifouling and bactericidal functionalities in a single coating combines the advantages of each, increasing the probability that bacterial colonization can be successfully inhibited. This Review highlights recent developments in dual-functional polymer-based antibacterial coatings for specific biomedical applications. General strategies for endowing surfaces with either antifouling or bactericidal polymeric coatings are first discussed, followed by more detailed descriptions of coatings with integrated antifouling and bactericidal functionalities that target the important biomedical applications: blood-contacting devices, orthopedic implants, wound dressings, ocular devices, urinary catheters, endotracheal tubes, and hospital textiles. The importance of tailoring the coatings to meet the specific constraints and requirements of the intended application beyond the antibacterial functionality is emphasized, and finally, the potential challenges in translating such coatings to clinical application are highlighted.

show abstract

Section: Dual-functional Coatings For Biomedical Applicationsmentioning

confidence: 99%

Polymer-Based Coatings with Integrated Antifouling and Bactericidal Properties for Targeted Biomedical Applications

Mitra

Kang

Neoh

2021

ACS Appl. Polym. Mater.

View full text Add to dashboard Cite

show abstract

“…[75] Silver and its formulations were studied in different polymeric surfaces, including silicone, polyurethane, and latex, and tested against a broad spectrum of Gram-positive and Gramnegative bacteria, in both in vitro and in vivo studies. [67,68,74,[76][77][78][79] For all these reasons, silver is a promising coating for ureteral stent devices, and it has been widely investigated for coating application in the urinary tract context. Nonetheless, contradicting studies already described the ineffectiveness of this strategy, reporting no significant advantages against UTIs.…”

Section: Coatingsmentioning

confidence: 99%

Future Directions for Ureteral Stent Technology: From Bench to the Market

Domingues

Pacheco

Cruz

et al. 2021

Advanced Therapeutics

View full text Add to dashboard Cite

Ureteral stents are broadly used for the treatment of a wide range of pathologies, with different complexities and characteristics. Despite being efficient, the morbidity associated with stents, such as bacterial infection and pain, limits their therapeutic action and often represents an increase in healthcare costs. As no single solution fits all problems, there is still a need to improve these medical devices. Throughout this review, the most recent innovations are outlined and suggestions regarding future directions for ureteral stent technology are formulated with respect to materials, coatings, and designs of these devices. As highlighted here, during the process of passing these innovations to the growing market of ureteral stents, one of the biggest challenges is to increase the predictive value of the in vitro assays and, consequently, reduce the number of in vivo tests needed. Thus, recommendations concerning in vitro standard testing of these devices are provided, with focus on medium, flow conditions, and microbiological parameters. Additionally, the reader is also presented with insights about a crucial but rarely discussed topic, the bureaucratic part of the bench to market process, particularly the product certification legislation in Europe.

show abstract

“…Antibiotic therapies may affect not only the target microorganisms but also the hostassociated microbial communities, particularly those in the intestine [29]. In MS and SCI patients, neurogenic lower urinary tract dysfunction, respiratory and skin problems frequently occur [30] and hence this population is at risk of developing infections that often require antibiotic treatment [31,32]. Therefore, they might also be at risk of altered gut microbiota composition.…”

Section: Introductionmentioning

confidence: 99%

Faecal Microbiota in Patients with Neurogenic Bowel Dysfunction and Spinal Cord Injury or Multiple Sclerosis—A Systematic Review

Faber

Stolwijk-Swüste

Ginkel

et al. 2021

JCM

View full text Add to dashboard Cite

Background: Neurogenic bowel dysfunction (NBD) frequently occurs in patients with spinal cord injury (SCI) and multiple sclerosis (MS) with comparable symptoms and is often difficult to treat. It has been suggested the gut microbiota might influence the course of NBD. We systematically reviewed the literature on the composition of the gut microbiota in SCI and MS, and the possible role of neurogenic bowel function, diet and antibiotic use. Methods: A systematic search was conducted in PubMed and Embase, which retrieved studies on the gut microbiota in SCI and MS. The Newcastle–Ottawa Quality Assessment Scale (NOS) was used to assess methodological quality. Results: We retrieved fourteen papers (four on SCI, ten on MS), describing the results of a total of 479 patients. The number of patients per study varied from 13 to 89 with an average of 34. Thirteen papers were observational studies and one study was an intervention study. The studies were case control studies in which the gut microbiota composition was determined by 16S rRNA gene sequencing. The methodological quality of the studies was mostly rated to be moderate. Results of two studies suggested that alpha diversity in chronic SCI patients is lower compared to healthy controls (HC), whereas results from five studies suggest that the alpha diversity of MS patients is similar compared to healthy subjects. The taxonomic changes in MS and SCI studies are diverse. Most studies did not account for possible confounding by diet, antibiotic use and bowel function. Conclusion: Based on these 14 papers, we cannot draw strong conclusions on the composition of the gut microbiota in SCI and MS patients. Putatively, alpha diversity in chronic SCI patients may be lower compared to healthy controls, while in MS patients, alpha diversity may be similar or lower compared to healthy controls. Future studies should provide a more detailed description of clinical characteristics of participants and of diet, antibiotic use and bowel function in order to make valid inferences on changes in gut microbiota and the possible role of diet, antibiotic use and bowel function in those changes.

show abstract

A randomized controlled trial to assess the efficacy and cost-effectiveness of urinary catheters with silver alloy coating in spinal cord injured patients: trial protocol

Cited by 9 publications

References 16 publications

Polymer-Based Coatings with Integrated Antifouling and Bactericidal Properties for Targeted Biomedical Applications

Polymer-Based Coatings with Integrated Antifouling and Bactericidal Properties for Targeted Biomedical Applications

Future Directions for Ureteral Stent Technology: From Bench to the Market

Faecal Microbiota in Patients with Neurogenic Bowel Dysfunction and Spinal Cord Injury or Multiple Sclerosis—A Systematic Review

Contact Info

Product

Resources

About